As well as OCR, also other therapies for MS aim to mitigate the inflammatory state: some studies have reported altered L-Kynurenine levels and Kyn/Trp ratios in MS patients during treatment with IFN-β (49) or glucocorticoids (50). The gene discussed is IFNB1; the disease is myeloid sarcoma.